Related Experiment Videos
Cisapride in management of chronic pediatric constipation
1Department of Pediatrics, University of Jordan, Amman.
Insights
Cisapride effectively improved stool frequency and reduced gastrointestinal transit time in children with chronic idiopathic constipation. This study suggests cisapride is a potential treatment for pediatric constipation.
Area of Science:
- Pediatric Gastroenterology
- Pharmacology
Background:
- Chronic idiopathic constipation (CIC) is a common pediatric condition.
- Current treatment options for pediatric CIC can be limited.
Purpose of the Study:
- To evaluate the efficacy of cisapride in treating chronic idiopathic constipation in children.
- To assess cisapride's impact on stool frequency and gastrointestinal transit time.
Main Methods:
- A double-blind, placebo-controlled study involving 73 children with CIC.
- Phase I: Lactulose disimpaction. Phase II: 8 weeks of cisapride (0.3 mg/kg qid) or placebo.
- Stool frequency and total gastrointestinal transit time were primary outcome measures.
Main Results:
- Cisapride significantly increased weekly stool frequency compared to placebo (p < 0.05).
- Cisapride significantly reduced total gastrointestinal transit time compared to baseline and placebo (p < 0.05).
- Placebo showed no significant effect on stool frequency or transit time.
Conclusions:
- Cisapride demonstrates efficacy in managing chronic idiopathic constipation in pediatric patients.
- Cisapride may be a valuable therapeutic option for improving bowel function in children with CIC.
Background:
This study was conducted to explore the use of cisapride in the treatment of chronic idiopathic constipation in children.
Methods:
Seventy-nine children were screened. Seventy-three of them met the selection criteria that included clinical, laboratory, radiologic, and histopathologic investigations. These patients entered a week-long phase I of disimpaction using lactulose. Four of them were noncompliant and thus were excluded from the next phase. In phase II sixty-nine patients were assigned to two treatment groups: 0.3 mg/kg cisapride four times a day versus matching placebo for 8 weeks in a double-blind study. The two groups that completed phase II were similar in age and duration of symptoms, confirmed by statistical analysis. Stool frequency was assessed weekly, beginning at the end of the disimpaction phase and continuing for 9 weeks. Total gastrointestinal transit time was measured twice, on completion of phase I and 9 weeks later. Transit time is the time required for a carmine marker taken orally after overnight fast to appear in the stool.
Results:
There was a significant difference between stool frequency per week before and after cisapride treatment, stool frequency per week at the end of phase II with cisapride versus placebo, and total gastrointestinal transit time before and after treatment with cisapride (p < 0.05 for all values). No such difference was demonstrated when comparing stool frequency per week or total gastrointestinal transit time before and after placebo (p > 0.05 for both).
Conclusions:
Cisapride may have a role in the management of chronic idiopathic constipation in children.